Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

BACKGROUND AND OBJECTIVES: Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity. It has been developed for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Jani, Rajendra H., Kansagra, Kevinkumar, Jain, Mukul R., Patel, Harilal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824340/
https://www.ncbi.nlm.nih.gov/pubmed/24062180
http://dx.doi.org/10.1007/s40261-013-0128-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824340/
https://www.ncbi.nlm.nih.gov/pubmed/24062180
http://dx.doi.org/10.1007/s40261-013-0128-3

Ejemplares similares